These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19789873)

  • 1. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.
    von Heideman A; Berglund A; Larsson R; Nygren P
    Cancer Chemother Pharmacol; 2010 May; 65(6):1165-72. PubMed ID: 19789873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I study of CHS 828 in patients with solid tumor malignancy.
    Hovstadius P; Larsson R; Jonsson E; Skov T; Kissmeyer AM; Krasilnikoff K; Bergh J; Karlsson MO; Lönnebo A; Ahlgren J
    Clin Cancer Res; 2002 Sep; 8(9):2843-50. PubMed ID: 12231525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer agent CHS-828 inhibits cellular synthesis of NAD.
    Olesen UH; Christensen MK; Björkling F; Jäättelä M; Jensen PB; Sehested M; Nielsen SJ
    Biochem Biophys Res Commun; 2008 Mar; 367(4):799-804. PubMed ID: 18201551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.
    Ravaud A; Cerny T; Terret C; Wanders J; Bui BN; Hess D; Droz JP; Fumoleau P; Twelves C
    Eur J Cancer; 2005 Mar; 41(5):702-7. PubMed ID: 15763645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.
    Holen K; Saltz LB; Hollywood E; Burk K; Hanauske AR
    Invest New Drugs; 2008 Feb; 26(1):45-51. PubMed ID: 17924057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.
    Isambert N; Campone M; Bourbouloux E; Drouin M; Major A; Yin W; Loadman P; Capizzi R; Grieshaber C; Fumoleau P
    Eur J Cancer; 2010 Mar; 46(4):729-34. PubMed ID: 20031390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of pazopanib in patients with advanced cancer.
    Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
    Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.
    Rodriguez GI; Jones RE; Orenberg EK; Stoltz ML; Brooks DJ
    Clin Cancer Res; 2002 Sep; 8(9):2828-34. PubMed ID: 12231523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
    J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer.
    Pourgholami MH; Szwajcer M; Chin M; Liauw W; Seef J; Galettis P; Morris DL; Links M
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):597-605. PubMed ID: 19904538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
    Hjarnaa PJ; Jonsson E; Latini S; Dhar S; Larsson R; Bramm E; Skov T; Binderup L
    Cancer Res; 1999 Nov; 59(22):5751-7. PubMed ID: 10582695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
    Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.